LEGN Legend Biotech Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: LEGN

Price (delayed)

$18.45

Market cap

$3.58B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.5

Enterprise value

$2.89B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 42
Highlights
The EPS has surged by 72% year-on-year and by 63% since the previous quarter
The company's net income has surged by 72% YoY and by 63% QoQ
The quick ratio has grown by 46% from the previous quarter but it has contracted by 36% YoY
The gross margin has contracted by 9% YoY but it has grown by 2.9% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.legendbiotech.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of LEGN

LEGN stock price

How has the Legend Biotech stock price performed over time
Intraday
-1.02%
1 week
8.53%
1 month
-15.44%
1 year
-43.97%
YTD
-15.13%
QTD
-36.11%

Financial performance

How have Legend Biotech's revenue and profit performed over time
Revenue
$1.27B
Gross profit
$719.12M
Operating income
-$55.25M
Net income
-$91.69M
Gross margin
56.6%
Net margin
-7.2%
The operating margin has soared by 85% YoY and by 64% QoQ
Legend Biotech's net margin has surged by 82% YoY and by 67% QoQ
LEGN's operating income has soared by 75% year-on-year and by 59% since the previous quarter
The company's net income has surged by 72% YoY and by 63% QoQ

Price vs fundamentals

How does LEGN's price correlate with its fundamentals

Growth

What is Legend Biotech's growth rate over time

Valuation

What is Legend Biotech stock price valuation
P/E
N/A
P/B
2.79
P/S
2.7
EV/EBIT
N/A
EV/EBITDA
256.95
EV/Sales
2.27
The EPS has surged by 72% year-on-year and by 63% since the previous quarter
The stock's price to book (P/B) is 70% less than its 5-year quarterly average of 9.3 and 36% less than its last 4 quarters average of 4.4
The equity is up by 27% from the previous quarter and by 19% YoY
The P/S is 93% less than the 5-year quarterly average of 40.1 and 38% less than the last 4 quarters average of 4.4
The revenue has surged by 60% year-on-year and by 12% since the previous quarter

Efficiency

How efficient is Legend Biotech business performance
The return on sales has surged by 92% year-on-year and by 86% since the previous quarter
LEGN's return on invested capital has surged by 87% year-on-year and by 83% since the previous quarter
LEGN's return on assets has surged by 72% year-on-year and by 64% since the previous quarter
The company's return on equity has surged by 72% YoY and by 65% QoQ

Dividends

What is LEGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LEGN.

Financial health

How did Legend Biotech financials performed over time
The quick ratio has grown by 46% from the previous quarter but it has contracted by 36% YoY
Legend Biotech's current ratio has increased by 43% QoQ but it has decreased by 35% YoY
Legend Biotech's debt is 77% lower than its equity
The debt to equity has contracted by 43% from the previous quarter and by 38% YoY
Legend Biotech's debt has decreased by 29% QoQ and by 28% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.